These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 8493429)

  • 21. Scientific review of EORTC trials: the functioning of the New Treatment Committee and Protocol Review Committee.
    Lardot C; Steward W; Van Glabbeke M; Armand JP
    Eur J Cancer; 2002 Mar; 38 Suppl 4():S24-30. PubMed ID: 11858960
    [TBL] [Abstract][Full Text] [Related]  

  • 22. American Society of Clinical Oncology policy statement: oversight of clinical research.
    American Society of Clinical Oncology
    J Clin Oncol; 2003 Jun; 21(12):2377-86. PubMed ID: 12721281
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Quantifying the bias in the estimated treatment effect in randomized trials having interim analyses and a rule for early stopping for futility.
    Walter SD; Han H; Briel M; Guyatt GH
    Stat Med; 2017 Apr; 36(9):1506-1518. PubMed ID: 28183155
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Size of cancer clinical trials and stopping rules.
    Pocock SJ
    Br J Cancer; 1978 Dec; 38(6):757-66. PubMed ID: 369589
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The independent statistician for data monitoring committees.
    DeMets DL; Fleming TR
    Stat Med; 2004 May; 23(10):1513-7. PubMed ID: 15122729
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Monitoring rules for stopping accrual in comparative survival studies.
    Rubinstein LV; Gail MH
    Control Clin Trials; 1982 Dec; 3(4):325-43. PubMed ID: 7160190
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Stopping guidelines for an effectiveness trial: what should the protocol specify?
    Tyson JE; Pedroza C; Wallace D; D'Angio C; Bell EF; Das A
    Trials; 2016 May; 17(1):240. PubMed ID: 27165260
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Perspective: human immunodeficiency virus type 1 (HIV-1) RNA end points in HIV clinical trials: issues in interim monitoring and early stopping.
    Zackin R; Marschner I; Andersen J; Cowles MK; De Gruttola V; Hammer S; Fischl M; Cotton D
    J Infect Dis; 1998 Mar; 177(3):761-5. PubMed ID: 9498459
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adaptive Designs with Discrete Test Statistics and Consideration of Overrunning.
    Schmidt R; Burkhardt B; Faldum A
    Methods Inf Med; 2015; 54(5):434-46. PubMed ID: 26429500
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Some practical aspects of the interim monitoring of clinical trials.
    Simon R
    Stat Med; 1994 Jul 15-30; 13(13-14):1401-9. PubMed ID: 7973219
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Policies for clinical trials in cancer].
    Suemasu K
    Gan No Rinsho; 1988 Jan; 34(1):7-12. PubMed ID: 3339851
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Data monitoring and interim analyses in the pharmaceutical industry: ethical and logistical considerations.
    Rockhold FW; Enas GG
    Stat Med; 1993 Mar; 12(5-6):471-9. PubMed ID: 8493425
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The use of data monitoring committees in Canadian trial groups.
    Pater JL
    Stat Med; 1993 Mar; 12(5-6):505-8. PubMed ID: 8493428
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Data monitoring boards in the pharmaceutical industry.
    Herson J
    Stat Med; 1993 Mar; 12(5-6):555-61; discussion 563. PubMed ID: 8493431
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Stopping clinical trials by design.
    Whitehead J
    Nat Rev Drug Discov; 2004 Nov; 3(11):973-7. PubMed ID: 15520819
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Data monitoring committees and capturing relevant information of high quality.
    Fleming TR
    Stat Med; 1993 Mar; 12(5-6):565-70; discussion 571-3. PubMed ID: 8493432
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A decision rule for sequential monitoring of clinical trials with a primary and supportive outcome.
    Zhao Y; Grambsch PM; Neaton JD
    Clin Trials; 2007; 4(2):140-53. PubMed ID: 17456513
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The NHLBI model: a 25 year history.
    Friedman L
    Stat Med; 1993 Mar; 12(5-6):425-31. PubMed ID: 8493421
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Data monitoring in clinical trials: the case for stochastic curtailment.
    Davis BR; Hardy RJ
    J Clin Epidemiol; 1994 Sep; 47(9):1033-42. PubMed ID: 7730906
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The early termination of clinical trials: causes, consequences, and control. With special reference to trials in the field of arrhythmias and sudden death. Task Force of the Working Group on Arrhythmias of the European Society of Cardiology.
    Eur Heart J; 1994 Jun; 15(6):721-38. PubMed ID: 8088260
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.